Sign In
Buy ICCC
ImmuCell Earnings Calls
| Release date | May 14, 2026 |
| EPS estimate | $0.0500 |
| EPS actual | $0.210 |
| EPS Surprise | 320.00% |
| Revenue estimate | 5.401M |
| Revenue actual | 10.357M |
| Revenue Surprise | 91.77% |
| Release date | Mar 04, 2026 |
| EPS estimate | -$0.0100 |
| EPS actual | -$0.310 |
| EPS Surprise | -3,000.00% |
| Revenue estimate | 5.4M |
| Revenue actual | 7.626M |
| Revenue Surprise | 41.22% |
| Release date | Nov 13, 2025 |
| EPS estimate | - |
| EPS actual | -$0.0200 |
| Revenue estimate | - |
| Revenue actual | 5.506M |
| Release date | Aug 14, 2025 |
| EPS estimate | - |
| EPS actual | $0.0600 |
| Revenue estimate | - |
| Revenue actual | 6.445M |
Last 4 Quarters for ImmuCell
Below you can see how ICCC performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 14, 2025 |
| Price on release | $6.72 |
| EPS estimate | - |
| EPS actual | $0.0600 |
| Date | Price |
|---|---|
| Aug 08, 2025 | $6.66 |
| Aug 11, 2025 | $6.66 |
| Aug 12, 2025 | $6.65 |
| Aug 13, 2025 | $6.53 |
| Aug 14, 2025 | $6.72 |
| Aug 15, 2025 | $6.10 |
| Aug 18, 2025 | $6.11 |
| Aug 19, 2025 | $5.90 |
| Aug 20, 2025 | $6.04 |
| 4 days before | 0.90% |
| 4 days after | -10.08% |
| On release day | -9.18% |
| Change in period | -9.27% |
| Release date | Nov 13, 2025 |
| Price on release | $6.05 |
| EPS estimate | - |
| EPS actual | -$0.0200 |
| Date | Price |
|---|---|
| Nov 07, 2025 | $6.10 |
| Nov 10, 2025 | $6.31 |
| Nov 11, 2025 | $6.27 |
| Nov 12, 2025 | $6.13 |
| Nov 13, 2025 | $6.05 |
| Nov 14, 2025 | $5.40 |
| Nov 17, 2025 | $4.91 |
| Nov 18, 2025 | $4.56 |
| Nov 19, 2025 | $4.74 |
| 4 days before | -0.82% |
| 4 days after | -21.65% |
| On release day | -10.74% |
| Change in period | -22.30% |
| Release date | Mar 04, 2026 |
| Price on release | $6.46 |
| EPS estimate | -$0.0100 |
| EPS actual | -$0.310 |
| EPS surprise | -3,000.00% |
| Date | Price |
|---|---|
| Feb 26, 2026 | $6.55 |
| Feb 27, 2026 | $6.57 |
| Mar 02, 2026 | $6.54 |
| Mar 03, 2026 | $6.40 |
| Mar 04, 2026 | $6.46 |
| Mar 05, 2026 | $6.35 |
| Mar 06, 2026 | $6.60 |
| Mar 09, 2026 | $6.48 |
| Mar 10, 2026 | $6.63 |
| 4 days before | -1.37% |
| 4 days after | 2.63% |
| On release day | -1.70% |
| Change in period | 1.22% |
| Release date | May 14, 2026 |
| Price on release | $8.26 |
| EPS estimate | $0.0500 |
| EPS actual | $0.210 |
| EPS surprise | 320.00% |
| Date | Price |
|---|---|
| May 08, 2026 | $8.05 |
| May 11, 2026 | $8.45 |
| May 12, 2026 | $8.38 |
| May 13, 2026 | $8.36 |
| May 14, 2026 | $8.26 |
| May 15, 2026 | $8.92 |
| May 18, 2026 | $9.91 |
| May 19, 2026 | $10.20 |
| May 20, 2026 | $9.88 |
| 4 days before | 2.61% |
| 4 days after | 19.61% |
| On release day | 7.99% |
| Change in period | 22.73% |
ImmuCell Earnings Call Transcript Summary of Q1 2026
ImmuCell reported strong operational and financial progress in Q1 2026 driven by a focused strategy on its calf scours prevention franchise (First Defense/Tri-Shield). Product sales reached a company milestone with the first-ever >$10 million revenue quarter ($10.4M), domestic sales grew ~35.7%, and gross margin expanded to 45% despite a ~2.4% headwind from legacy Re-Tain cost shifts. Net income rose 34% year-over-year to $1.9M ($0.21/share) and EBITDA improved to $2.6M. Tri-Shield showed especially strong demand and premium pricing power, helping ImmuCell expand U.S. category share (estimated share of spend up to 35.2% and treated-animal share to 18.1%). Management is executing manufacturing yield improvements (monthly output reached ~450,000 units) while planning a major capacity expansion funded in part by a $2M settlement with a former contract manufacturer. The company is expanding its U.S. commercial footprint (adding a third new territory) and is taking a disciplined, prioritized approach to international expansion. Key investor takeaways: commercialization momentum and margin recovery are evident, manufacturing capacity remains the critical execution risk/opportunity, and management is investing to convert strong demand into sustained revenue growth.
